Presentation is loading. Please wait.

Presentation is loading. Please wait.

BA Supplementary Fig. S1. A, quantification of RIP1 expression levels in melanocytic tumors. Data shown are mean immunoreactive score (IRS) ± S.E.M. of.

Published byKerrie Sutton Modified over 8 years ago

Similar presentations

Presentation on theme: "BA Supplementary Fig. S1. A, quantification of RIP1 expression levels in melanocytic tumors. Data shown are mean immunoreactive score (IRS) ± S.E.M. of."— Presentation transcript:

1 BA Supplementary Fig. S1. A, quantification of RIP1 expression levels in melanocytic tumors. Data shown are mean immunoreactive score (IRS) ± S.E.M. of three individual experiments. *P<0.05, Kruskal-Wallis test. B, quantification of RIP1 positive cells in melanocytic tumors. Data shown are RIP1 positive cells (%) ± S.E.M. of three individual experiments. *P<0.05, Kruskal-Wallis test.

2 Supplementary Fig. S2. Melanocytes of different origin express similarly lower levels of RIP1 than melanoma cell lines. Whole cell lysates from HEMa-LP, HEMn-DP, HEMn-MP melanocytes and IgR3, Mel-RM, ME4405 melanoma cells were subjected to western blotting.

3 A B Supplementary Fig. S3. Increase in cell death and proliferation triggered by overexpression of RIP1 is independent of its kinase domain. A, MM200.RIP1 and IgR3.RIP1 (Tet.RIP1), and their corresponding vector control cells (Tet.Ctrl) treated with tetracycline (1 µg/ml), z-VAD-fmk (30 µM) or Necrostatin-1 (30 µM) as indicated for 24 hours were subjected to CellTiter-Glo cell viability assays (n=3, mean±S.E.M.). B, MM200 and IgR3 cells transiently transfected with empty vector or RIP1-K45A (kinase-dead RIP1) constructs were subjected to CellTiter-Glo cell viability assays (n=3, mean±S.E.M.). C, MM200.RIP1 and IgR3.RIP1 treated with tetracycline (1 µg/ml) and Necrostatin-1 (30 µM) as indicated for 72 hours were subjected to BrdU incorporation assays (n=3, mean±S.E.M.). *P<0.05, Student’s t-test. C

4 Supplementary Fig. S4. NF-kB is constitutively activated at high levels in melanoma cells compared to melanocytes. HEMn-MP melanocytes, MM200, IgR3, Mel-RM and ME4405 cells transiently transfected with NF-κB reporter constructs for 24 hours were subjected to NF-κB reporter assays (n=3, mean±S.E.M.). *P<0.05, Student’s t-test.

5 Supplementary Fig. S5. RIP1 overexpression reduced viability of melanocytes by ~10% in a caspase- dependent manner. HEMn-MP melanocytes transduced with empty vector or RIP1 cDNA constructs were treated with z-VAD-fmk at 6 hours after transduction. After another 18 hours, cells were subjected to CellTiter-Glo cell viability assays (n=3, mean±S.E.M.).

6 A B Supplementary Fig. S6. mRNA expression levels and copy number variation of RIP1 in fresh melanoma isolates. A, quantitative reverse transcription-PCR analysis of total RNA extracted from melanocytes and fresh melanoma isolates. The relative abundance of RIP1 mRNA expression in melanocytes was arbitrarily designated as 1 (n=3, mean±S.E.M.). B, quantitative PCR analysis of genomic DNA extracted from melanocytes and fresh melanoma isolates. The relative copy number of RIP1 in melanocytes was arbitrarily designated as 1.

7 Supplementary Fig. S7. The turnover rates of the RIP1 mRNA remain comparable between melanoma and melanocytes. Quantitative reverse transcription-PCR analysis of total RNA extracted from melanocytes, MM200 and Mel-RM cells treated with 5 µg/ml actinomycin D (Act D) for indicated periods. The relative abundance of RIP1 mRNA expression in melanocytes at 0h was arbitrarily designated as 1 (n=3, mean±S.E.M.).

8 AB Supplementary Figure S8. Knockdown of TNFR1 reduces activation of NF-kB and decreases proliferation in melanoma cells, which can be abolished by overexpression of RIP1. Mel-RM and ME4405 cells were transiently transfected with control siRNA (Ctrl siRNA), TNFR1 siRNA and RIP1 cDNA constructs as indicated. A, 24 hours after transfection, cells were subjected to NF-κB reporter assays (n=3, mean±S.E.M.). *P<0.05, Student’s t-test. B, 72 hours after transfection, cells were subjected to BrdU incorporation assays (n=3, mean±S.E.M.). *P<0.05, Student’s t-test.

9 Melanocytic tumorsNumber RIP1 expression levels (IRS) b %RIP1 positive melanoma cells Compound Nevus103.851 c (37-68) d Dysplastic Nevus104.162.8 (40-78) Thin Primary (<1mm Breslow depth) 2013.781.3 (57-100) Thick Primary (>1mm Breslow depth) 2014.489.4 (65-100) Lymph Node Metastases2012.885.8 (53-100) Distant Metastases2011.475.9 (53-100) a The cohort of the melanocytic tumors used in this study was the same to that reported before (27). b IRS: Immunoreactive score. c Numbers stand for the mean percentage of positive cells. d Numbers in brackets represent the range of positive cells. Supplementary Table S1, Summary of melanocytic tumors and their positivity for RIP1 a

Download ppt "BA Supplementary Fig. S1. A, quantification of RIP1 expression levels in melanocytic tumors. Data shown are mean immunoreactive score (IRS) ± S.E.M. of."

Similar presentations

Supplementary Figure 1: Co-treatment with SAHA and PLX4720 increases the level of a ~50kD fragment of PARP. Whole cell lysates from MM200 and Sk-Mel-28.

Supplementary Figure 1: Co-treatment with SAHA and PLX4720 increases the level of a ~50kD fragment of PARP. Whole cell lysates from MM200 and Sk-Mel-28.
Supplementary Figure 1. AB Supplementary Figure 1. L1 and Alu retrotransposition assay. A. Schematic of L1 retrotransposition plasmid (L1). ORF1 and ORF2.

Supplementary Figure 1. AB Supplementary Figure 1. L1 and Alu retrotransposition assay. A. Schematic of L1 retrotransposition plasmid (L1). ORF1 and ORF2.
WT Hras G12V WT+TPA Hras G12V +TPA Hras G12V +TPA H&EKi67 Supplementary Fig 1: H&E and IHC staining for Ki67 in sections of mouse skin and papilloma from.

WT Hras G12V WT+TPA Hras G12V +TPA Hras G12V +TPA H&EKi67 Supplementary Fig 1: H&E and IHC staining for Ki67 in sections of mouse skin and papilloma from.
A B Supplementary Figure 1: A, TRAIL-induced apoptosis in melanoma cells and melanocytes. Cells were treated with TRAIL (200ng/ml) for 24 hours before.

A B Supplementary Figure 1: A, TRAIL-induced apoptosis in melanoma cells and melanocytes. Cells were treated with TRAIL (200ng/ml) for 24 hours before.
Figure S1. RNA-seq results for caveolin-1 (Cav1). Upper panel: UCSC genome browser view. Lower panel: quantification o f Cav1 expression based on RNA-seq.

Figure S1. RNA-seq results for caveolin-1 (Cav1). Upper panel: UCSC genome browser view. Lower panel: quantification o f Cav1 expression based on RNA-seq.
Lopez de Silanes et al. Suppl-Fig.1 0 10 50 100 246 DNMT3b in HuR siRNA cells t 1/2 (Untr)=2.13 h t 1/2 (Cispl)=3.27 h 0246 0 t 1/2 (Cispl)>8 h t 1/2 (Untr)>8.

Lopez de Silanes et al. Suppl-Fig DNMT3b in HuR siRNA cells t 1/2 (Untr)=2.13 h t 1/2 (Cispl)=3.27 h t 1/2 (Cispl)>8 h t 1/2 (Untr)>8.
SKOV3 ~44% SKBR3 ~6% SiHa ~89% CaSki i ~67% HeLa ~89% Supplementary Figure 1 Huisman et al Supplementary Figure 1. DNA methylation status of the EPB41L3.

SKOV3 ~44% SKBR3 ~6% SiHa ~89% CaSki i ~67% HeLa ~89% Supplementary Figure 1 Huisman et al Supplementary Figure 1. DNA methylation status of the EPB41L3.
Con WTTM Supplementary Figure 1 Supplementary Figure 1. Tumor histopathology of the lungs. (a) Histological examination of lungs of 52-week-old K- ras.

Con WTTM Supplementary Figure 1 Supplementary Figure 1. Tumor histopathology of the lungs. (a) Histological examination of lungs of 52-week-old K- ras.
B Supplementary Fig S1. (A) ZR75- and MCF7-PELP1 knockdown cells were generated as described in methods section. Pooled colonies were analyzed for PELP1.

B Supplementary Fig S1. (A) ZR75- and MCF7-PELP1 knockdown cells were generated as described in methods section. Pooled colonies were analyzed for PELP1.
Supplementary Figure S1 Inhibition of AKT and S6 phosphorylation. After 4 h treatment with 1 µM of GDC-0941, EVSA-T parental, resistant Clone1, Clone2,

Supplementary Figure S1 Inhibition of AKT and S6 phosphorylation. After 4 h treatment with 1 µM of GDC-0941, EVSA-T parental, resistant Clone1, Clone2,
Wu et al., Supplementary Fig 1 Supplementary Figure 1: The depletion of BRG1 in HeLa cells has no effect on cell proliferation. Sh- empty vector was used.

Wu et al., Supplementary Fig 1 Supplementary Figure 1: The depletion of BRG1 in HeLa cells has no effect on cell proliferation. Sh- empty vector was used.
Figure S1 A B Figure S1. SPATA2 is required for TNFα or zVAD.fmk induced necroptosis in L929 cells. (A) L929 cells were transfected with a pool of four.

Figure S1 A B Figure S1. SPATA2 is required for TNFα or zVAD.fmk induced necroptosis in L929 cells. (A) L929 cells were transfected with a pool of four.
IL-18 Downregulates Collagen Production in Human Dermal Fibroblasts via the ERK Pathway  Hee Jung Kim, Seok Bean Song, Jung Min Choi, Kyung Moon Kim,

IL-18 Downregulates Collagen Production in Human Dermal Fibroblasts via the ERK Pathway  Hee Jung Kim, Seok Bean Song, Jung Min Choi, Kyung Moon Kim,
Supplemental Digital Content 4

Supplemental Digital Content 4
Cell Physiol Biochem 2015;36: DOI: /

Cell Physiol Biochem 2015;36: DOI: /
A Signal Transduction Pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its Correlation with Progression in Human Melanoma  Xuan Qu, Liangliang Shen,

A Signal Transduction Pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its Correlation with Progression in Human Melanoma  Xuan Qu, Liangliang Shen,
Volume 19, Issue 7, Pages (July 2017)

Volume 19, Issue 7, Pages (July 2017)
SIRT1 Regulates the Chemoresistance and Invasiveness of Ovarian Carcinoma Cells  David Hamisi Mvunta, Tsutomu Miyamoto, Ryoichi Asaka, Yasushi Yamada,

SIRT1 Regulates the Chemoresistance and Invasiveness of Ovarian Carcinoma Cells  David Hamisi Mvunta, Tsutomu Miyamoto, Ryoichi Asaka, Yasushi Yamada,
Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin 

Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin 
A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation  Lily Mahapatra, Neal Andruska, Chengjian Mao,

A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation  Lily Mahapatra, Neal Andruska, Chengjian Mao,

Similar presentations

Ads by Google